{"organizations": [], "uuid": "0410326f92dad71ad29da631f6c2b50957df26b3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-cidara-says-additional-data-confir/brief-cidara-says-additional-data-confirm-positive-results-in-antifungal-rezafungin-idUSASC09T5C", "country": "US", "domain_rank": 408, "title": "BRIEF-Cidara Says Additional Data Confirm Positive Results In Antifungal Rezafungin", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-21T14:09:00.000+02:00", "replies_count": 0, "uuid": "0410326f92dad71ad29da631f6c2b50957df26b3"}, "author": "", "url": "https://www.reuters.com/article/brief-cidara-says-additional-data-confir/brief-cidara-says-additional-data-confirm-positive-results-in-antifungal-rezafungin-idUSASC09T5C", "ord_in_thread": 0, "title": "BRIEF-Cidara Says Additional Data Confirm Positive Results In Antifungal Rezafungin", "locations": [], "entities": {"persons": [], "locations": [{"name": "antifun", "sentiment": "none"}], "organizations": [{"name": "rezafungin reuters", "sentiment": "none"}, {"name": "cidara therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 11 PM / Updated 8 minutes ago BRIEF-Cidara Says Additional Data Confirm Positive Results In Antifungal Rezafungin Reuters Staff March 21 (Reuters) - Cidara Therapeutics Inc: * CIDARA THERAPEUTICS PROVIDES CLINICAL DATA UPDATES FOR ITS LEAD ANTIFUNGAL REZAFUNGIN * CIDARA THERAPEUTICS - ADDITIONAL DATA AND ANALYSES FROM STRIVE PHASE 2 CLINICAL TRIAL CONFIRM POSITIVE EFFICACY RESULTS IN BOTH REZAFUNGIN ARMS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-21T14:09:00.000+02:00", "crawled": "2018-03-21T14:28:33.003+02:00", "highlightTitle": ""}